Study to Assess the Compliance of Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2018
Price : $35 *
At a glance
- Drugs Iloprost (Primary)
- Indications Embolism and thrombosis; Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms COMPHI
- Sponsors Bayer
- 03 May 2017 Status changed from active, no longer recruiting to completed.
- 12 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov